Summary:
- Neuren Pharmaceuticals, a biopharmaceutical company, has secured its third FDA Fast Track designation for its drug candidate NNZ-2591.
- The Fast Track designation is a process designed to facilitate the development and expedite the review of drugs that treat serious or life-threatening conditions.
- This designation for NNZ-2591 is a significant milestone, as it indicates the potential of the drug to address an unmet medical need and could lead to a faster approval process.